quinacrine has been researched along with Pancreatic Neoplasms in 5 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinacrine is a repositioned drug with an anticancer activity but suffers a limited ability to reach tumor cells." | 1.62 | Undaria pinnatifida fucoidan nanoparticles loaded with quinacrine attenuate growth and metastasis of pancreatic cancer. ( Abdallah, OY; Bary, AA; Elnaggar, YSR; Etman, SM; Mehanna, RA, 2021) |
| "Quinacrine is an antimalarial drug that was repositioned for treatment of cancer." | 1.56 | Lactoferrin/Hyaluronic acid double-coated lignosulfonate nanoparticles of quinacrine as a controlled release biodegradable nanomedicine targeting pancreatic cancer. ( Abdallah, OY; Elnaggar, YSR; Etman, SM; Mehanna, RA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Etman, SM | 2 |
| Abdallah, OY | 2 |
| Mehanna, RA | 2 |
| Elnaggar, YSR | 2 |
| Bary, AA | 1 |
| Imaida, K | 1 |
| Furukawa, F | 1 |
| Nishikawa, A | 1 |
| Imazawa, T | 1 |
| Kasahara, K | 1 |
| Takahashi, M | 1 |
| Kreuser, ED | 1 |
1 review available for quinacrine and Pancreatic Neoplasms
| Article | Year |
|---|---|
[Malignant pleural effusions. Pathophysiology, diagnosis and therapy].
Topics: Absorption; Amylases; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Capillary Permea | 1985 |
4 other studies available for quinacrine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Lactoferrin/Hyaluronic acid double-coated lignosulfonate nanoparticles of quinacrine as a controlled release biodegradable nanomedicine targeting pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Movement; Cell Surv | 2020 |
Undaria pinnatifida fucoidan nanoparticles loaded with quinacrine attenuate growth and metastasis of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Male; Mice; Mice, I | 2021 |
Undaria pinnatifida fucoidan nanoparticles loaded with quinacrine attenuate growth and metastasis of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Male; Mice; Mice, I | 2021 |
Undaria pinnatifida fucoidan nanoparticles loaded with quinacrine attenuate growth and metastasis of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Male; Mice; Mice, I | 2021 |
Undaria pinnatifida fucoidan nanoparticles loaded with quinacrine attenuate growth and metastasis of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Male; Mice; Mice, I | 2021 |
Delayed toxicity associated with morphological changes in animal experiments.
Topics: Animals; Carcinogenicity Tests; Carcinogens; Drug Evaluation, Preclinical; Male; Pancreatic Neoplasm | 1996 |
Enhancing effects of quinacrine on development of hepatopancreatic lesions in N-nitrosobis(2-oxopropyl)amine-initiated hamsters.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinogens; Cricetinae; Drug Synergism; Female; Kidney | 1998 |